Login / Signup

Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections.

Sarah RoweSarah GreenBenjamin AlbrechtStephanie M Pouch
Published in: Open forum infectious diseases (2023)
Dalbavancin is a promising option in patients who require long-term suppression for chronic gram-positive LVAD infections, given its unique pharmacokinetic profile and excellent tissue penetration. The use of biweekly dalbavancin infusions in our 8 patients prevented infection for an extended period of time despite some of the patients not being able to consistently receive infusions. Larger studies are needed to determine the efficacy and safety of using dalbavancin for long-term suppression of gram-positive LVAD infections.
Keyphrases
  • end stage renal disease
  • left ventricular assist device
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • gram negative
  • peritoneal dialysis
  • case control